The world is set to get a new and potentially more effective drug for treating cancerous skin and the spread of the common cold, thanks to a fungus-based medicine.
The new drug is called CSLA, or Clostridium Lactis A.S.L. and has been tested by researchers in the United States.
The US National Institutes of Health (NIH) announced that it has approved the drug, called CSP-7, for the treatment of cancers, including melanoma and multiple myeloma.
The drug, developed by a team led by Dr. David W. Miller of the NIH’s National Institute of Allergy and Infectious Diseases, has been undergoing clinical trials and regulatory approval in the US.
CSL-7 will be available to patients with melanoma, multiple myelloma, and multiple types of non-Hodgkin’s lymphoma in the next few weeks.
Dr. Miller said CSL and its derivatives have been approved by the FDA in the past two years.
“We believe we have found a novel therapeutic agent for the disease of nonlinear cell proliferation, a cancerous cell-cycle pathway,” Dr. W.
L Miller said.
“With the use of a novel peptide, the treatment may lead to new therapeutic options for melanoma.”
Dr. Johnson and Dr. Omid Abi-Mekdad, the NIH-funded head of the Center for Biotechnology and Biological Sciences at Emory University in Atlanta, Georgia, said the study demonstrates the benefits of a compound that’s already available on the market.
“This compound has the potential to offer significant therapeutic benefits for many cancers including melanomas,” Dr Johnson said.
The team’s study, published online in the journal Science, is the first of its kind to look at the potential for a cancer treatment to treat nonlinear growth.
In a previous study published in the same journal, the team looked at CSL, a peptide that’s been shown to block growth of certain cells in skin cells.
The researchers said that the study was a first step in showing that CSL could potentially work in cancer.
“The potential for CSL to act on cancer cells and target tumor progression is enormous,” Dr Abi Mekdad said.
CSP is made by a gene-editing technique known as CRISPR.
The CRISP enzyme was recently identified in bacteria and fungi that make CRISPs.
Dr Miller and Dr Johnson also found that the CRISR enzyme works on cells that are similar to melanoma cells, and that CSP has a potent inhibitory effect.
In fact, they said the compound can have “a significant effect on the progression of melanoma by blocking melanin production and killing melanocytes.”
The researchers say CSP can be used to treat cancer of the skin.
Cylindrical proteins known as cyclophilins that form the base of the fungus CSL act as a scaffold to attach proteins to the surface of cells.
These proteins bind to the skin’s surface, and then grow over the entire cell membrane, attaching to the cells’ nucleus.
CCLs also bind to DNA and allow the growth of a new type of cancerous cells called beta-galactosidases.
In addition, the researchers found that CCL inhibitors block the activity of melanin, a pigment that makes up the body’s skin.
“It has been hypothesized that the presence of CSL on skin can act as an effective inhibitor of melanogenesis,” Dr Miller said in a statement.
“In addition, melanocytes secrete melanin in response to certain stimuli, such as light, and in response, melanin synthesis occurs.
It is also known that CGLP-1, a melanocortin-1 receptor, can inhibit melanogenesis.
It has also been proposed that the inhibitory activity of CCL is mediated by melanocatalin receptor.”
CSL was discovered by Dr Miller’s lab in the late 1990s.
He has been studying the function of the fungi in skin for years.
He first discovered that CRLs and CCL could bind to melanin when they were discovered in 2007.
CTL is a compound found in certain fungi and can block the production of melanosomes.
It also has been used in the treatment for melanomas.
CRL is a member of the family of peptides known as CSLs, which are used to bind to proteins.
In the past, CCL and CSL were used to block cancer growth.
The protein-based drugs were first found to have potent anti-cancer effects in a clinical trial in mice.
In that trial, researchers injected the protein-containing CCL into mice with melanomas and melanomas of the same type that were caused by melanoma.
After three months, the mice who received CCL showed significant reductions in the number of melanomas compared to those who received control mice. CLL-2,